When prescribing or dispensing unregistered medicines, understanding how patient medications are monitored across Australia is an important part of safe and compliant clinical practice.

Real-Time Prescription Monitoring (RTPM) systems give prescribers and pharmacists access to information about a patient’s monitored medicine history to support informed clinical decisions.

In our latest article, we break down the different systems across Australia, how the traffic-light alerts work, and why RTPM is a clinical decision-support tool — not a barrier to patient care.

Compliance doesn't stop with clinics and prescribers. In Part Two of our TGA reporting series, we break down the record-keeping and reporting obligations for importers, pharmacies, manufacturers and sponsors.

As regulators share more data and close reporting gaps, businesses that treat compliance as a strategic priority will be best placed for sustainable growth.

New South Wales has passed significant reforms to medicinal cannabis driving laws, providing greater protection for eligible patients who test positive for THC but are not impaired. Learn more about the reforms, what they mean in practice, and when the new laws are expected to come into effect.

In this interview, we sat down with Fadi Roumieh to talk about his journey into medicinal cannabis, how clinician attitudes have shifted over the years, the myths that still surround the industry, and where he sees cannabinoid medicine heading next.

As Australia’s medicinal cannabis sector rapidly expands, regulatory oversight from the TGA is becoming increasingly strict.

Non-compliance carries risks far beyond financial penalties, it can cost businesses their reputation, operational capabilities, and patient trust.

Discover key insights on why robust compliance frameworks are essential for sustainable growth.

Navigating medicinal cannabis compliance in Australia requires more than meeting initial regulatory approvals. As the Therapeutic Goods Administration (TGA) increases its focus on reporting, governance, pharmacovigilance and advertising compliance, businesses must implement strong systems to remain compliant. Learn the essential reporting obligations and best practices for operating successfully in Australia's evolving medicinal cannabis market.

Vertical integration is transforming Australia's medicinal cannabis industry. While connected clinics, pharmacies and patient support can improve access and efficiency, success depends on maintaining clinical independence, strong governance and patient-first care.

We sat down with Penny Murdoch  – a valued team member at EQWELLIBRIYUM, a qualified naturopath, and a medicinal cannabis industry representative – to discuss her unique career journey, the importance of evidence-based education, and how scientific knowledge helps healthcare professionals make informed clinical decisions.

The Department of Veterans Affairs (DVA) updated its Medicinal Cannabis Framework with those changes likely to reshape how clinics deliver care to veteran patients — representing a structural shift in how care must be delivered, documented, and justified under DVA funding pathways.

A case study highlighting an increasingly important reality within the Australian medicinal cannabis industry - that many clinics are operating on inefficient commercial structures without realising stronger opportunities may exist.

Regulation alone doesn’t create access – and innovation alone doesn’t change perception.

In our latest interview, Dr. Shabnam Sarshar unpacks the deeper challenges facing medicinal cannabis from clinician education to cultural stigma, and why women’s health remains one of the most overlooked frontiers.

Our latest series is all about insights into entering the Australian medicinal cannabis market in 2026. This post breaks down the evolution of the industry from early regulatory barriers to today’s competitive, highly scrutinised landscape and what it signals for the future.

With close to a decade of experience in Australia’s medicinal cannabis industry, Georgie Lutz is a highly respected industry leader and co-founder of Bosman Clinic. We were thrilled to interview her about her journey in the sector, exploring how the industry has evolved and discussing the importance of transparency, clinical independence, and why patient-led models must shape the future of the sector.

Australia’s medicinal cannabis sector is evolving and so are patient expectations.

With patients becoming more informed, more selective, and more willing to change providers if their experience doesn’t meet expectations.In our latest blog, Medicinal Cannabis Patients: Preferences & Perspectives, we explore what patients actually value today and the trends clinics should be preparing for as the market continues to mature.

Whether you're a clinic operator, healthcare professional, or industry stakeholder, understanding these shifts is key to building sustainable, patient-centred care models.

Understanding the patient pathway to medicinal cannabis in Australia can be a major hurdle for businesses . 
Our latest blog post breaks down the entire journey from clinical assessment to TGA approval, highlighting the critical operational frameworks businesses need to support Australian patients effectively.

This article explores the role of pharmacists in dispensing medicinal cannabis, with a focus on patient access, continuity of care, and quality oversight.

Professor Kylie O’Brien shares her insights on the evolving medicinal cannabis landscape — from evidence gaps and ongoing misconceptions to regulatory challenges and emerging research.

As a leading scientific expert and recent co-author of Medicinal Cannabis in Women’s Health, she offers a clear, grounded perspective on what the industry needs next and how clinical practice can better align with the science.

Get to know Adam Isaac Miller, one of Australia’s most influential and longstanding voices in the medicinal cannabis landscape. With nearly eleven years of experience spanning clinical, regulatory, commercial, and policy domains.

Unpack the experiences that have defined his journey — from his deeply personal introduction to cannabis, to the milestones that have shaped his career, the lessons he’s learned advising stakeholders across the ecosystem, and the honest concerns and hopes he holds for the future of the industry.

Medicinal cannabis in Australia is rapidly evolving — where what was once a niche market is now a significant part of modern healthcare. For businesses navigating this landscape, understanding these dual pressures is key to thriving in this fast-paced and dynamic environment.

Get to know Sharlene Mavor,  medical scientist specialising in medicinal cannabis research and the Co-Founder and Managing Director of Medicinal Cannabis Research Australia (MCRA). Sharlene is a trailblazer within the industry in her own right and for this blog post, we’ve got her to answer some informative questions about her journey, her opinion on the industry, and what brands & businesses can learn from it.